1. Arterioscler Thromb Vasc Biol
Identification and Assessment of Plasma Lysozyme as a Putative Biomarker of Atherosclerosis
by Vahitha B. Abdul-Salam, Punit Ramrakha, Unni Krishnan, David R. Owen, Joseph Shalhoub, Alun H. Davies, Tjun Y. Tang, Jonathan H. Gillard, Joseph J. Boyle, Martin R. Wilkins, and Robert J. Edwards
Arterioscler Thromb Vasc Biol
Volume 30(5):
May 1, 2010
Copyright © American Heart Association, Inc. All rights reserved.

2. Figure 1. Biomarker discovery in arterial plasma.
Figure 1. Biomarker discovery in arterial plasma. SELDI-TOF MS was used to compare the plasma protein profiles of patients with 3VD (n=20) with those of patients with NV (n=20) (cohort 1). A, Representative SELDI-TOF MS spectra; the m/z ion is indicated by arrows. B, Volcano plot summarizing comparative differences of the entire data set of 143 detected ions between patients with NV and patients with 3VD. Dotted lines indicate boundaries of statistical significance (P<0.01, t test) and 2-fold difference. C, Comparative levels of the m/z ion. D, After identification of the m/z ion, lysozyme levels were determined by EIA. Statistically significant differences (t test) between the patient groups are indicated.
Vahitha B. Abdul-Salam et al. Arterioscler Thromb Vasc Biol. 2010;30:
Copyright © American Heart Association, Inc. All rights reserved.

3. Figure 2. Arterial plasma lysozyme and CRP levels in patients undergoing diagnostic coronary angiography and carotid endarterectomy.
Figure 2. Arterial plasma lysozyme and CRP levels in patients undergoing diagnostic coronary angiography and carotid endarterectomy. Box-and-whisker plots indicate median, interquartile distribution, and range of arterial plasma lysozyme (A) and CRP (B) levels. Statistically significance differences in lysozyme levels vs the NV group from either cohort 2 or cohort 3 are indicated as ### and ***, respectively (P<0.001, t test). The corresponding CRP levels were not significantly different (P>0.05).
Vahitha B. Abdul-Salam et al. Arterioscler Thromb Vasc Biol. 2010;30:
Copyright © American Heart Association, Inc. All rights reserved.

4. Figure 3. Venous plasma lysozyme in patients with atherosclerosis.
Figure 3. Venous plasma lysozyme in patients with atherosclerosis. Venous plasma lysozyme levels were measured in patients with carotid atherosclerosis from the ATHEROMA study before treatment with atorvastatin (pre-AVS) and after treatment for 12 weeks with either 10 mg/d (n=13) or 80 mg/d (n=21) of AVS. Levels are compared with those determined in individuals with NV (n=16) and 3VD (n=17) from cohort 2. Statistically significant differences between groups are indicated and were determined using the unpaired or paired t test, as appropriate.
Vahitha B. Abdul-Salam et al. Arterioscler Thromb Vasc Biol. 2010;30:
Copyright © American Heart Association, Inc. All rights reserved.